Sotirios Zarogiannis

Prof. Sotirios Zarogiannis

Faculty of Medicine, University of Thessaly
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Ourania S. KotsiouOurania S. Kotsiou
Ourania S. Kotsiou
KGKonstantinos I. Gourgoulianis
Konstantinos I. Gourgoulianis
Sotirios ZarogiannisSotirios Zarogiannis
Sotirios Zarogiannis
Interleukin 33 (IL-33) is highly expressed in barrier sites, acting via the suppression of tumorigenicity 2 receptor (ST2). IL-33/ST2 axis has long been known to play a pivotal role in immunity and cell homeostasis by promoting wound healing and tissue repair. However, it is also involved in the loss of balance between extensive inflammation and tissue regeneration lead to remodeling, the hallmark of fibrosis. The aim of the current review is to critically evaluate the available evidence regarding the role of the IL-33/ST2 axis in organ fibrosis. The role of the axis in tissue remodeling is better understood considering its crucial role reported in organ development and regeneration. Generally, the IL-33/ST2 signaling pathway has mainly anti-inflammatory/anti-proliferative effects; however, chronic tissue injury is responsible for pro-fibrogenetic responses. Regarding pulmonary fibrosis mature IL-33 enhances pro-fibrogenic type 2 cytokine production in an ST2- and macrophage-dependent manner, while full-length IL-33 is also implicated in the pulmonary fibrotic process in an ST2-independent, Th2-independent fashion. In liver fibrosis, evidence indicate that when acute and massive liver damage occurs, the release of IL-33 might act as an activator of tissue-protective mechanisms, while in cases of chronic injury IL-33 plays the role of a hepatic fibrotic factor. IL-33 signaling has also been involved in the pathogenesis of acute and chronic pancreatitis. Moreover, IL-33 could be used as an early marker for ulcer-associated activated fibroblasts and myofibroblast trans-differentiation; thus one cannot rule out its potential role in inflammatory bowel disease-associated fibrosis. Similarly, the upregulation of the IL-33/ST2 axismay contribute to tubular cell injury and fibrosis via epithelial to mesenchymal transition (EMT) of various cell types in the kidneys. Of note, IL-33 exerts a cardioprotective role via ST2 signaling, while soluble ST2 has been demonstrated as a marker of myocardial fibrosis. Finally, IL-33 is a crucial cytokine in skin pathology responsible for abnormal fibroblast proliferation, leukocyte infiltration and morphologic differentiation of human endothelial cells. Overall, emerging data support a novel contribution of the IL-33/ST2 pathway in tissue fibrosis and highlight the significant role of the Th2 pattern of immune response in the pathophysiology of organ fibrosis.

4 October 2018 in Seminars in Dialysis
Verified
Journal Article
Closed access
PDF file
Vassilios LiakopoulosVassilios Liakopoulos
Vassilios Liakopoulos
Stefanos RoumeliotisStefanos Roumeliotis
Stefanos Roumeliotis
Sotirios ZarogiannisSotirios Zarogiannis
Sotirios Zarogiannis
Theodoros EleftheriadisTheodoros Eleftheriadis
Theodoros Eleftheriadis
PMPeter R. Mertens
Peter R. Mertens

14 September 2015 in Journal of Sleep Research
Verified
Journal Article
Closed access
PDF file
GVGeorge Vavougios
George Vavougios
GNGeorge Natsios
George Natsios
CPChaido Pastaka
Chaido Pastaka
Sotirios ZarogiannisSotirios Zarogiannis
Sotirios Zarogiannis
KGKonstantinos I. Gourgoulianis
Konstantinos I. Gourgoulianis

18 March 2015 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
KVKonstantinos Vogiatzidis
Konstantinos Vogiatzidis
Sotirios ZarogiannisSotirios Zarogiannis
Sotirios Zarogiannis
IAIsaac Aidonidis
Isaac Aidonidis
ESEvgeniy I. Solenov
Evgeniy I. Solenov
PMPaschalis-Adam Molyvdas
Paschalis-Adam Molyvdas
CHChrissi Hatzoglou
Chrissi Hatzoglou
The pericardium is one of the serosal cavities of the mammals. It consists of two anatomical structures closely connected, an external sac of fibrous connective tissue, that is called fibrous pericardium and an internal that is called serous pericardium and coats the internal surface of the fibrous pericardium (parietal layer) and the heart (visceral layer) forming the pericardial space. Between these two layers a small amount of fluid exists that is called pericardial fluid. The pericardial fluid is a product of ultrafiltration and is considered to be drained by lymphatic capillary bed mainly. Under normal conditions it provides lubrication during heart beating while the mesothelial cells that line the membrane may also have a role in the absorption of the pericardial fluid along with the pericardial lymphatics. Here we provide a review of the the current literature regarding the physiology of the pericardial space and the regulation of pericardial fluid turnover and highlight the areas that need to be further investigated.

Verified
Journal Article
Open access
PDF file
RJRajesh Jagirdar
Rajesh Jagirdar
ABAndreas Bozikas
Andreas Bozikas
Sotirios ZarogiannisSotirios Zarogiannis
Sotirios Zarogiannis
MBMaria Bartosova
Maria Bartosova
CSClaus Peter Schmitt
Claus Peter Schmitt
Vassilios LiakopoulosVassilios Liakopoulos
Vassilios Liakopoulos
Encapsulating peritoneal sclerosis (EPS) is a life-threatening complication of long-term peritoneal dialysis (PD), which may even occur after patients have switched to hemodialysis (HD) or undergone kidney transplantation. The incidence of EPS varies across the globe and increases with PD vintage. Causative factors are the chronic exposure to bioincompatible PD solutions, which cause long-term modifications of the peritoneum, a high peritoneal transporter status involving high glucose concentrations, peritonitis episodes, and smoldering peritoneal inflammation. Additional potential causes are predisposing genetic factors and some medications. Clinical symptoms comprise signs of intestinal obstruction and a high peritoneal transporter status with incipient ultrafiltration failure. In radiological, macro-, and microscopic studies, a massively fibrotic and calcified peritoneum enclosed the intestine and parietal wall in such cases. Empirical treatments commonly used are corticosteroids and tamoxifen, which has fibrinolytic properties. Immunosuppressants like azathioprine, mycophenolate mofetil, or mTOR inhibitors may also help with reducing inflammation, fibrin deposition, and collagen synthesis and maturation. In animal studies, N-acetylcysteine, colchicine, rosiglitazone, thalidomide, and renin-angiotensin system (RAS) inhibitors yielded promising results. Surgical treatment has mainly been performed in severe cases of intestinal obstruction, with varying results. Mortality rates are still 25–55% in adults and about 14% in children. To reduce the incidence of EPS and improve the outcome of this devastating complication of chronic PD, vigorous consideration of the risk factors, early diagnosis, and timely discontinuation of PD and therapeutic interventions are mandatory, even though these are merely based on empirical evidence.

10 January 2023 in Immunity
Verified
Journal Article
Open access
AGAnastasios D. Giannou
Anastasios D. Giannou
JKJan Kempski
Jan Kempski
ASAhmad Mustafa Shiri
Ahmad Mustafa Shiri
JLJöran Lücke
Jöran Lücke
TZTao Zhang
Tao Zhang
Samuel HuberSamuel Huber
Samuel Huber
During metastasis, cancer cells invade, intravasate, enter the circulation, extravasate, and colonize target organs. Here, we examined the role of interleukin (IL)-22 in metastasis. Immune cell-derived IL-22 acts on epithelial tissues, promoting regeneration and healing upon tissue damage, but it is also associated with malignancy. Il22-deficient mice and mice treated with an IL-22 antibody were protected from colon-cancer-derived liver and lung metastasis formation, while overexpression of IL-22 promoted metastasis. Mechanistically, IL-22 acted on endothelial cells, promoting endothelial permeability and cancer cell transmigration via induction of endothelial aminopeptidase N. Multi-parameter flow cytometry and single-cell sequencing of immune cells isolated during cancer cell extravasation into the liver revealed iNKT17 cells as source of IL-22. iNKT-cell-deficient mice exhibited reduced metastases, which was reversed by injection of wild type, but not Il22-deficient, invariant natural killer T (iNKT) cells. IL-22-producing iNKT cells promoting metastasis were tissue resident, as demonstrated by parabiosis. Thus, IL-22 may present a therapeutic target for prevention of metastasis.